TY - JOUR
T1 - Future pandemics and vaccination: Public opinion and attitudes across three European countries
AU - Determann, D
AU - de Bekker - Grob, Esther
AU - French, J
AU - Voeten, HA
AU - Richardus, Jan hendrik
AU - Das, E
AU - Korfage, Ida
PY - 2016
Y1 - 2016
N2 - Background: Understanding public opinion and attitudes regarding vaccination is crucial for successful outbreak management and effective communication at the European level. Methods: We explored national differences by conducting focus group discussions in The Netherlands, Poland and Sweden. Discussions were structured using concepts from behavioural models. Results: Thematic analysis revealed that participants would base their vaccination decision on trade-offs between perceived benefits and barriers of the vaccine also taking into account the seriousness of the new outbreak. Except for those having chronic diseases, participants expected a low infection risk, resulting in a low willingness to get vaccinated. Information about the health status of cases was considered important since this might change perceived susceptibility. Participants displayed concerns about vaccine safety due to the limited available time to produce and test vaccines in the acute situation of a new pandemic. Swedish participants mentioned their tendency of doing the right thing and following the rules, as well as to get vaccinated because of solidarity with other citizens and social influences. This appeared much less prominent for the Dutch and Polish participants. However, Swedish participants indicated that their negative experiences during the Influenza A/H1N1 2009 pandemic decreases their acceptance of future vaccinations. Polish participants lacked trust in their national (public) health system and government, and were therefore sceptical about the availability and quality of vaccines in Poland. Conclusions: Although participants overall expressed similar considerations, important differences between countries stand out, such as previous vaccination experiences, the degree of adherence to social norms, and the degree of trust in health authorities. (C) 2016 The Authors. Published by Elsevier Ltd.
AB - Background: Understanding public opinion and attitudes regarding vaccination is crucial for successful outbreak management and effective communication at the European level. Methods: We explored national differences by conducting focus group discussions in The Netherlands, Poland and Sweden. Discussions were structured using concepts from behavioural models. Results: Thematic analysis revealed that participants would base their vaccination decision on trade-offs between perceived benefits and barriers of the vaccine also taking into account the seriousness of the new outbreak. Except for those having chronic diseases, participants expected a low infection risk, resulting in a low willingness to get vaccinated. Information about the health status of cases was considered important since this might change perceived susceptibility. Participants displayed concerns about vaccine safety due to the limited available time to produce and test vaccines in the acute situation of a new pandemic. Swedish participants mentioned their tendency of doing the right thing and following the rules, as well as to get vaccinated because of solidarity with other citizens and social influences. This appeared much less prominent for the Dutch and Polish participants. However, Swedish participants indicated that their negative experiences during the Influenza A/H1N1 2009 pandemic decreases their acceptance of future vaccinations. Polish participants lacked trust in their national (public) health system and government, and were therefore sceptical about the availability and quality of vaccines in Poland. Conclusions: Although participants overall expressed similar considerations, important differences between countries stand out, such as previous vaccination experiences, the degree of adherence to social norms, and the degree of trust in health authorities. (C) 2016 The Authors. Published by Elsevier Ltd.
U2 - 10.1016/j.vaccine.2015.12.035
DO - 10.1016/j.vaccine.2015.12.035
M3 - Article
C2 - 26740251
SN - 0264-410X
VL - 34
SP - 803
EP - 808
JO - Vaccine
JF - Vaccine
IS - 6
ER -